This article first appeared on GuruFocus .
Release Date: November 05, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
ANI Pharmaceuticals Inc ( NASDAQ:ANIP ) reported Q3 2026 total revenues of $290.8 million, up 28% year-over-year, with adjusted EBITDA of $83.3 million, up 40% year-over-year.
-
Rare disease net revenues grew 36% year-over-year, driven by strong performance of Cortrophin Gel and Alluvian.
-
Generics business continued to outperform, with revenue of $104.5 million, up 11% year-over-year, and 16 generic launches year-to-date.
-
The proposed acquisition of Aegidus Therapeutics adds Emcetate, the first and only approved treatment for MCT8 deficiency, with peak sales potential over $300 million and durable IP protection into mid-2045.
-
ANI Pharmaceuticals Inc ( NASDAQ:ANIP ) raised its 2026 adjusted non-GAAP EBITDA guidance to $290-$300 million and non-GAAP EPS to $9.37-$9.71, reflecting strong profitability.
Negative Points
-
Cortrophin Gel net revenues came in lighter than expected at $138.7 million, leading ANI Pharmaceuticals Inc ( NASDAQ:ANIP ) to revise 2026 Cortrophin guidance down to $480-$500 million from $520-$540 million.
-
Specialty pharmacy network capacity constraints due to higher-than-anticipated demand caused slower conversion of new gout cases to patients on therapy.
-
The gout expansion into primary care and podiatry faced a longer-than-expected ramp as new prescribers needed additional support for the enrollment-to-fulfillment process.
-
The Aegidus acquisition is expected to be dilutive to adjusted EBITDA and non-GAAP EPS in year one due to launch investments, with pro forma net leverage rising to approximately 2.7x.
-
ANI Pharmaceuticals Inc ( NASDAQ:ANIP ) did not provide 2027 revenue guidance for Emcetate, leaving uncertainty about the launch trajectory and peak sales timing.
Q & A Highlights
Q: On Cortrophin, was the Q3 shortfall driven by volume or revenue conversion, and would you have hit prior guidance without the conversion issues? A: CEO Nikhil Lalwani said demand at the top of the funnel was strong across existing specialties and the gout expansion, with new cases initiated in the five months since the May gout launch roughly 85% higher than the prior five months. He said that without the revenue conversion dynamics, ANI "absolutely" would have achieved its prior Q3 guidance. The revised guidance does not assume full benefits of the remediation efforts, though early improvements in time to first fill are already visible.
Q: What are the financial terms of the Aegidus Therapeutics offer, and how will ANI fund it? A: CEO Nikhil Lalwani said ANI is offering $560 million in total equity consideration, implying an enterprise value of about $434 million net of $95 million in expected proceeds from Aegidus' sale of its pediatric rare disease priority review voucher. The all-cash deal will be funded with existing cash and up to $300 million of debt backed by a new committed bridge facility from JPMorgan. Pro forma net leverage is expected at about 2.7x at closing, with the deal expected to close in late 2026 or early 2027.
Q: How large is the U.S. Emcitate opportunity, and how quickly can the 60 Expanded Access Program patients convert to commercial drug? A: CEO Nikhil Lalwani said more than 100 U.S. patients have been genetically validated, with about 60 on the EAP and roughly 300 patients treated globally across the EAP and Global Managed Access Program. The first priority is securing payer coverage and ensuring continuity of care as EAP patients transition to commercial drug, followed by treating validated but untreated patients. Management declined to give 2027 Emcitate revenue guidance, saying it will discuss the trajectory as the deal closes.
Q: What caused the Cortrophin specialty pharmacy bottleneck, and how long will it persist? A: CEO Nikhil Lalwani said demand generation significantly exceeded expectations, pressuring specialty pharmacy network capacity and slowing reimbursement processing for both gout and existing specialty cases. ANI has strengthened support at existing specialty pharmacies, expanded its network into high-demand regions, and added patient support staff for primary care and podiatry offices new to ACTH. He said early signs of improving fulfillment are visible, with record existing-specialty volumes in October and modestly shorter time to first fill in late Q3 and early Q4.
Q: What is the U.S. pricing for Emcitate, and how does it compare with ex-U.S. pricing? A: CEO Nikhil Lalwani said Aegidus set the wholesale acquisition cost at $74,026 per pack, equating to roughly $950,000 annualized based on the average daily dose of about 740 micrograms observed in the Triac Trial 1. He said pricing reflects the value of the first approved therapy for an ultra-rare, life-shortening disease with no prior treatment options and is in line with other ultra-rare indications, with U.S. and ex-U.S. pricing set separately given the larger patient population outside the U.S.
Q: How is the gout expansion performing in terms of prescriber breadth and depth? A: CEO Nikhil Lalwani said the number of prescribers rose 67% versus Q2, with 40% of primary care and podiatry prescribers initiating two or more cases, and new cases initiated doubled quarter over quarter. He noted more than half of Cortrophin prescribers overall were previously naive to ACTH, and the addressable acute gouty arthritis flare population is about 285,000 patients out of roughly 10 million gout patients, leaving the market significantly underpenetrated.
Q: Could the specialty pharmacy bottleneck have been anticipated, and would ANI reconsider the scale of its primary care and podiatry expansion? A: CEO Nikhil Lalwani said ANI expected demand to increase but the actual demand generation significantly exceeded its original expectations, compounded by new prescribers ramping up on the enrollment-to-fulfillment process. He said ANI will not reconsider the extent of the expansion, citing the large underpenetrated ACTH market and early signs of use beyond gout in those offices. Near-term focus is on operational execution to deliver Q4 Cortrophin guidance and momentum into 2027.
Q: What were ANI's Q3 2026 financial results and updated guidance? A: CFO Stephen Carey reported total net revenues of $290.8 million, up 28% year over year, adjusted EBITDA of $83.3 million, up 40%, and adjusted non-GAAP diluted EPS of $2.70 versus $2.04 a year earlier. For 2026, ANI now guides total company net revenue of $1.085 billion to $1.125 billion, Cortrophin net revenue of $480 million to $500 million, Alluvia net revenue of $80 million to $85 million, adjusted EBITDA of $290 million to $300 million, and non-GAAP EPS of $9.37 to $9.71.
Q: How will ANI identify additional MCT8 deficiency patients beyond the roughly 100 already diagnosed in the U.S.? A: Chris Mutt, Senior Vice President and Head of ANI's Rare Disease Business, said the priority is disease education for pediatric neurologists, pediatric endocrinologists, and medical geneticists, since many physicians do not consider MCT8 deficiency because it is a newer disease entity and previously had no approved treatment. He added that advanced analytics using claims data can help find patients misdiagnosed with conditions such as cerebral palsy, and that an approved therapy gives physicians a reason to test.
Q: How is Emcitate administered, and how long do patients stay on therapy? A: Chris Mutt, Senior Vice President and Head of ANI's Rare Disease Business, said Emcitate is an oral tablet that can also be liquefied for administration through a G-tube, avoiding the need for patients to travel for infusions, a real advantage for this disabled population. CEO Nikhil Lalwani added that patients take the drug daily for life, with dosing adjusted based on patient weight using a scored tablet.
Q: What is the time to peak sales for Emcitate, and how much will ex-U
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
